Wei Wang,Kurunthachalam Kannan
Leaching of Phthalates from Medical Supplies and Their Implications for Exposure
phthalates,leaching,medical devices,intensive care unit,exposure
In this study, 72 single-use medical products, grouped into four categories, namely, creams/liquids (n = 8), medical devices (n = 46; 15 of 46 labeled “di(2-ethylhexyl)phthalate (DEHP)-free”), first aid products (n = 13), and intravenous (IV) infusion/irrigation fluids (n = 5), were collected from an intensive care unit in a hospital in New York State in 2015 and analyzed for the migration of 10 phthalates in ethanol/water (1:1) mixture for 1 h. The total phthalate concentration (Σphthalates) leached from medical products ranged from 0.04 to 54,600 μg. DEHP was the major phthalate found in 99% of the samples analyzed, with the highest amount leached from respiratory support devices (median: 6560 μg). DEHP was also found at notable concentrations in products labeled as “DEHP-free”. Direct exposure to phthalates from the use of medical devices and first aid supplies and dermal intake from the use of creams/lotions were calculated. The highest DEHP exposure dose of 730 μg/kg bw/day was determined from the use of cannula for neonates. This is the first study to document the amount of phthalates leached from various medical supplies and associated exposures.
Leaching of Phthalates from Medical Supplies and Their Implications for Exposure

In this study, 72 single-use medical products, grouped into four categories, namely, creams/liquids (n = 8), medical devices (n = 46; 15 of 46 labeled “di(2-ethylhexyl)phthalate (DEHP)-free”), first aid products (n = 13), and intravenous (IV) infusion/irrigation fluids (n = 5), were collected from an intensive care unit in a hospital in New York State in 2015 and analyzed for the migration of 10 phthalates in ethanol/water (1:1) mixture for 1 h. The total phthalate concentration (Σphthalates) leached from medical products ranged from 0.04 to 54,600 μg. DEHP was the major phthalate found in 99% of the samples analyzed, with the highest amount leached from respiratory support devices (median: 6560 μg). DEHP was also found at notable concentrations in products labeled as “DEHP-free”. Direct exposure to phthalates from the use of medical devices and first aid supplies and dermal intake from the use of creams/lotions were calculated. The highest DEHP exposure dose of 730 μg/kg bw/day was determined from the use of cannula for neonates. This is the first study to document the amount of phthalates leached from various medical supplies and associated exposures.

Phthalates, esters of ortho-phthalic acid, are widely used as plasticizers to improve the flexibility of polyvinyl chloride (PVC) plastics. Phthalates are present in consumer products, including personal care products (PCPs), pharmaceuticals, and medical devices. For over two decades, studies have shown that phthalates are reproductive and developmental toxicants and elicit carcinogenic, cardiotoxic, hepatotoxic, and nephrotoxic effects in laboratory animals. The effects of phthalates on the human endocrine system, especially on reproduction, are well documented. Di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP) are reproductive toxicants. DEHP has been widely used as a plasticizer in medical devices. Nevertheless, it is not known whether other phthalate diesters such as diethyl phthalate (DEP) and butyl benzyl phthalate (BzBP) are used in medical devices. Because phthalates are not chemically bound to the plastic matrix, they can be released from single-use disposable medical devices, such as infusion, transfusion, and dialysis systems or feeding tubes, resulting in considerable exposure among patients in hospital settings. It is well established that medical procedures are a source of DEHP exposure for patients, particularly infants under intensive care, dialysis patients, and blood donors. The risk from DEHP exposure among neonates, infants, and pregnant women in intensive care units has been investigated by several authors. Leaching of DEHP from plastic indwelling medical devices used in the pediatric intensive care unit has been associated with impaired cognitive development in 4 year old children after critical illness. Despite this, the magnitude of exposure from each of the medical devices is not well known. Empirical data, although limited, have demonstrated a positive association between exposure and the use of PVC tubings, catheters, and gloves. Few earlier studies have reported the occurrence of phthalates in medical devices in the United States. Nevertheless, leaching/migration studies of a wide range of phthalates (in addition to DEHP) from medical supplies have not been conducted to date. Furthermore, quantitative assessment of phthalate exposure from each of the medical devices/products has not been performed, and such information is crucial to develop strategies to mitigate exposures. In this study, 72 medical devices and products collected in 2015 from an intensive care unit in a hospital in New York State were tested for the leaching of 10 phthalate diesters, with the aim of determining concentrations, profiles, and exposures.

Ten phthalate diesters, namely, dimethyl phthalate (DMP), DEP, diisobutyl phthalate (DiBP), DBP, diallyl phthalate (DAP), di-n-hexyl phthalate (DnHP), benzyl butyl phthalate (BzBP), dicyclohexyl phthalate (DCHP), di(2-ethylhexyl) phthalate (DEHP), and di-n-octyl phthalate (DnOP), were analyzed. Nine d4 (deuterated) standards, d4-DMP, d4-DEP, d4-DiBP, d4-DBP, d4-DnHP, d4-BzBP, d4-DCHP, d4-DEHP, and d4-DnOP (AccuStandard, Inc. New Haven, CT), were used as internal standards. HPLC-grade ethanol was supplied by J. T. Baker (Phillipsburg, NJ). Ultrapure water (18.2 Ω) was generated using a Milli-Q system (Millipore, Billerica, MA). The chemical structures of phthalates analyzed in this study are shown in Table S1.

A total of 72 single-use medical devices and products comprising 8 cream/liquid samples, 46 devices, 13 first aid products, 4 intravenous (IV) fluids, and 1 irrigation fluid were obtained from an intensive care unit at a hospital in New York State in 2015. Description of the samples analyzed in this study is provided in Table S2. The medical supplies analyzed were categorized as medical devices, IV fluids/irrigation fluids, first aid products, and creams/liquids. Medical devices analyzed included baby products (e.g., nipple, pacifier, milk bottle, baby cloth, and baby diaper), medical tubing, syringe, catheter, connector, cannula, respiratory filter/support, IV fluid bag, blood pressure cuff and sensor pad, urine bag, plastic syringe, and clinical care supplies (e.g., fluidized positioner, lab diaper, and glove). In addition, first aid supplies (e.g., eye pad, gauze pad, abdominal pad, bandage, eyewash, burn cream, sterile alcohol prep pad, gauze, sting relief, plastic adhesive bandage, nitrile glove), medical creams/liquids (e.g., zinc oxide cream, liquid adhesive, baby wash), and IV fluids/irrigation fluids (saline, dextrose injection, sodium chloride injection, acetic acid injection, and fat emulsion IV infusion) were analyzed to represent varieties of medical supplies available in intensive care units. All samples analyzed were popular brands and distributed in hospitals throughout the United States. Samples were stored at 4 °C until analysis. To assess leaching of phthalates from medical devices and products, an ethanol/water mixture (1:1, v/v) was used as the simulant for extraction. This mixture has been suggested as an extraction solvent/simulant to assess leaching of DEHP from medical devices. For medical devies (such as syringes, tubes, baby products, and clinical care products) and first aid products, samples were filled/immersed with the simulant and equilibrated for 15 min, which was followed by sonication for 1 h. This was based on the assumption that the maximum volume/contact areas of products were considered for exposure. Deuterated (d4) internal standards of DMP, DEP, DiBP, DBP, DnHP, BzBP, DCHP, DEHP, and DnOP were fortified in sample extracts prior to liquid–liquid extraction (LLE) with ethyl acetate/n-hexane (50:50, v/v), as described previously. The organic extracts were concentrated under a gentle stream of nitrogen to 2 mL, and an aliquot was transferred into a gas chromatograph (GC) vial for instrumental analysis. The sample extraction roughly simulated the clinical use conditions of the devices that come into contact with blood or other solutions (e.g., saline, nutrient solution, blood, or medication). For IV infusion and irrigation fluid samples, such as saline and injection solutions, LLE was performed directly, after transferring these fluids out of bags/bottles. The volume of fluid extracted varied, depending on the amount packaged, which ranged from 50 to 1000 mL. It was assumed that each package was used fully per application, once opened. For medical cream/liquid samples, ∼0.05 g (wet weight) was transferred and extracted twice by shaking with 4 mL aliquots of methyl tert-butyl ether in a 12 mL glass tube for 30 min (after spiking internal standards, 1 mL of Milli-Q water, and equilibration for 15 min), followed by centrifugation at 2000 × g for 20 min. The combined extracts were divided into two equal aliquots and concentrated under a gentle stream of nitrogen, and one aliquot was reconstituted in hexane for GC–MS analysis.

Identification and quantification of phthalate diesters was achieved using gas chromatography (Agilent Technologies 6890N) coupled with mass spectrometry (MS; Agilent Technologies 5973). A fused-silica capillary column (DB-5; 30 m × 0.25 mm i.d.; 0.25 μm film thickness) was used for chromatographic separation of analytes. The oven temperature was programmed from 80 °C (held for 1.0 min) to 180 °C at 12 °C/min (held for 1.0 min), increased to 230 °C at 6 °C/min, then to 270 °C at 8 °C/min (held for 2.0 min), and finally, to 300 °C at 30 °C/min (held for 12.0 min). The limit of quantification (LOQ) was calculated from the lowest concentration of the calibration curve and a nominal sample weight of 1.0 g. The LOQs ranged from 1 to 50 ng/g, depending on the analyte. Samples were diluted and reanalyzed when concentrations exceeded the calibration range of the instrument. The mass spectrometer was operated in the selected ion monitoring mode, and ion fragments at m/z 163, 279, and 149 were monitored for the quantification of DMP, DnOP, and 7 other phthalate diesters, respectively. The fragment ions at m/z 177 for DEP, 233 for DiBP and DBP, 223 and 206 for BzBP, 167 for DCHP, 167 and 279 for DEHP, and 279 for DnHP were monitored for the confirmation of target compounds. Ion fragment at m/z 167 was monitored for d4-DMP and m/z 153 was monitored for other internal standards. Further details of the analysis are provided in the Supporting Information and have been described in detail elsewhere.

Adequate precaution was taken to eliminate phthalate contamination that could arise from laboratory materials and solvents, during the analysis of samples. All glassware and GC vials were rinsed with acetone, hexane, and dichloromethane in sequence and baked in an oven at 500 °C overnight to remove any residual phthalates that may be present. For each batch of samples, two procedural blanks, a spiked blank, a pair of matrix-spiked samples, and duplicate samples were analyzed. Trace levels of DEP (9.5–16.5 ng), DiBP (34.8–69.9 ng), and DEHP (46.5–66.3 ng) were found in procedural blanks (n = 3) analyzed with medical devices, DEHP (15.3–33.4 ng) was found in procedural blanks (n = 2) of first aid samples, and DEP (n.d.–1.06 ng) and DEHP (43.1–65.2 ng) were found in procedural blanks of medical cream/liquid samples. The concentrations of phthalates in medical supplies were subtracted from the mean values found in procedural blanks. Instrumental calibration was verified by the injection of standards ranging in phthalate concentrations from 0.1 to 1000 ng/mL, and the regression coefficient (R) of all calibration curves was >0.99. The recoveries of target compounds spiked into medical devices (64–115%) and cream/liquid samples (90–106%) are shown in Table S1. The concentrations of phthalates in samples (both medical devices and cream/liquid) were calculated using an isotope-dilution method, based on the responses of corresponding deuterated internal standards (except for DAP, which was calculated based on the response of d4-DnHP). Duplicate analysis of randomly selected samples yielded a coefficient variation of <15% for the concentrations of target analytes. A midpoint calibration standard was injected after every 20 samples, as a check for instrumental drift in sensitivity, and a pure solvent (hexane) was injected as a check for carryover of target chemicals from sample to sample. Concentrations below the LOQ were assigned a value of zero for data analysis. Data analysis was performed using SPSS version 17.0 (Amsterdam, The Netherlands). Statistical significance was set at p < 0.05.

On the basis of the median and maximum concentrations of phthalates measured in medical creams/liquids, we estimated daily dermal exposure doses (EDIcream/liquid) for adults, toddlers, infants, and neonates, as shown in eq 1where EDI is the daily dermal exposure dose (μg/kg bw/day), C is the measured concentration in creams/liquids (μg/g), M is the amount of daily use of creams/liquids (g), BW is the average body weight (kg), f1 is the retention factor (products retained by skin after use, f = 1), and f2 is the dermal absorption factor (f2 = 0.0011 for adults and f2 = 0.0021 for children). The values for M were obtained from the reports from the United States and Europe (1.4 g/day). The average body weights reported in the U.S. Exposure Factors Handbook for adults (80 kg), toddlers (14.6 kg), infants (8.3 kg), and neonates (5.35 kg) were applied. The daily exposure doses of phthalates through dermal absorption via baby clothes/diapers, blood pressure cuffs and sensor pads, and clinical care supplies (EDIdermal, μg/kg bw/day) were calculated using eq 2, where D is the amount of phthalate leached into the simulant in 60 min (μg). Each device/product was assumed to be used once a day.

EDIdirect (μg/kg bw/day) was calculated for products that result in direct exposure from the use of medical devices (e.g., fluids that pass through the tubing). Each device/solution was assumed to be used once a day. An estimate of intake based on the amount leached into the simulant (ethanol and Milli-Q water) in 60 min was calculated using eq 3

Medical creams/liquids are used in topical application for the treatment of wounds and rashes. Eight medical cream/liquid products (2 zinc oxide creams, 2 nasal zinc oxide creams, 2 baby washes, and 2 Mastisol liquid adhesives) were analyzed (see Table S2), and dermal exposure to phthalates was calculated (see Table S2). A few earlier studies reported the occurrence of phthalates in childcare lotion and cream products. Among 10 phthalates analyzed, the highest detection frequency was found for DEHP (100%) and DEP (75%), whereas DMP, DiBP, DBP, and BzBP were found only in a liquid adhesive (i.e., liquid band aid) sample. DEP was the major compound found at a mean concentration of 438 μg/g (range: n.d.–2050 μg/g), followed by DEHP (mean: 2.03 μg/g; range: 0.11–4.48 μg/g). A total phthalate (∑phthalates) concentration of 1750 μg/g was found in zinc oxide creams. Zinc oxide cream is a topical preparation that is applied to protect the skin from irritation, rashes, and sunburn.

Medical devices are used in procedures such as blood transfusion, extracorporeal membrane oxygenation, parenteral infusion, and hemodialysis. Phthalates leached from these devices are a direct source of exposure in patients, especially among preterm neonates in intensive care units. The medical devices (n = 46; Table S2) investigated in this study were single-use products including those used in parenteral nutrition/drug administration, nasogastric intubation (plastic tube that is inserted through the nose, past the throat, and into the stomach), oxygen delivery systems, respiratory support and air filter, baby care and clinical care products (fluidized positioner/diaper/glove), and fluid drainage. Six of the 10 phthalates were found in >85% of the medical devices analyzed, suggesting widespread application of phthalates in medical products. DEHP was found in 98% of the devices with a median amount of 22.3 μg (mean: 2340 μg; range: n.d.–54,600 μg) leached into the simulant in 60 min. The highest amount of 54,600 μg DEHP was leached from a neonatal expiratory filter set. A few earlier studies reported migration of phthalates from medical tubings, blood bags, and syringes. DEHP is widely used in PVC, which is applied in disposable medical examination and surgical gloves, flexible tubings used in the administration of parenteral solutions, and hemodialysis treatment. DiBP was the second most abundant compound leached into the simulant at a median amount of 0.18 μg (range: n.d.–340 μg), followed by DBP (median: 0.14 μg; range: n.d.–19.7 μg). The highest amount of DiBP (340 μg) was leached from urine collectors for newborns. Among various medical devices tested, the amount of DEHP leached from the respiratory support and filter (n = 4, median: 6560 μg and maximum: 54,600 μg) was the highest. The median and maximum amounts of DEHP leached from other medical devices were as follows: clinical care supplies (fluidized positioners/diapers/gloves) (n = 4; median: 440 μg, max: 17,680 μg) > blood pressure cuffs/sensors (n = 4; 341 μg, 2620 μg) > urine bags (n = 1; 109 μg) > syringes (n = 1; 41.3 μg) > IV fluid bags (n = 4; 16.9 μg, 3260 μg) > nipples/pacifiers/milk bottles (n = 4; 4.16 μg, 47.9 μg) > catheters (n = 4; 5.11 μg, 30.5 μg) > baby clothes/diapers (n = 4; 4.16 μg, 47.9 μg) > cannulas (n = 5; 1.66 μg, 3910 μg) > tubings (n = 6; 1.31 μg, 1730 μg) > connectors/extensions (n = 5; 0.36 μg, 331 μg). A high detection frequency (93%, n = 15) of DEHP in devices/products (in the general category of medical devices in this study) that were labeled “DEHP-free” was intriguing. However, the amounts of DEHP leached from those products were lower (median: 0.53 μg; range: n.d.–54,600 μg; p < 0.05) than those of other medical devices (median: 83.3 μg; 0.13–17,700 μg), suggesting the presence of smaller concentrations of DEHP in these products. The IV fluid bags were made of ethylene vinyl acetate (EVA) (labeled DEHP-free), PL 146 plastic (labeled as to contain DEHP), and PL325 plastic. Disposable syringes analyzed in this study were made of polypropylene resin. The highest amount of DEHP leached from IV fluid bags or syringes was from fluid bags made of PL146 plastic (3260 μg), followed by disposal plastic syringes (41.3 μg), whereas EVA and PL325 IV fluid bags leached 11.0–17.1 μg of DEHP into the simulant in 60 min. Although EVA bags were labeled as DEHP-free, >10 μg of DEHP was found to be leached into the simulant in 1 h.

We investigated the migration of phthalates from IV fluid bags into four types of infusion fluids (pediatric parenteral nutrition, 600 mL; dextrose 5% injection, 50 mL; 0.9% sodium chloride, 250 mL; and fat emulsion 20% infusion) and one type of irrigation solution (0.25% acetic acid) stored in a sterile plastic bottle. The IV fluid bags were filled with the infusion fluids (instead of water–ethanol simulant), and the fluids were directly extracted with ethyl acetate/n-hexane. DiBP, DBP, and DEHP were detected in all solutions, with the median amount of DEHP at 165 ng, followed by DEP (10.4 ng), DiBP (6.76 ng), and DBP (4.65 ng). DEHP was found in infusion solutions contained in all IV bags including those labeled DEHP-free. Nevertheless, the amount of DEHP leached into IV fluid was 1–2 orders of magnitude lower than that leached into the water/ethanol simulant, for the same IV bag (median 16.9 μg; range 11.0–3260 μg). These results suggest that the type of fluid that passes through the medical device is an important determinant on the amount of phthalate leached. The highest amount of ∑phthalates was detected in fat emulsion infusion (458 ng), which can be explained by the lipophilic nature of phthalates. The 0.25% acetic acid irrigating fluid leached the lowest amount of ∑phthalates from the IV bags (177 ng). A combination of the chemical composition of IV infusion fluid and the type of IV fluid bag are major determinants of DEHP leached from these products. Furthermore, the surface area of the product that comes into contact with the solution can affect the amount leached. The average concentration of DEHP in IV infusion fluids was 1.55 μg/L, indicating that each liter of fluid contains 1.55 μg DEHP, which was lower than the value reported earlier for IV infusion fluid stored in the polyethylene terephthalate (PET) container (10 μg/L).

Leaching of phthalates was examined in 13 single-use first aid supplies including sterile eye pads, antiseptics, sterile abdominal pads, sterile gauze pads, bandages, sting relief (towelette), burn creams, plastic adhesive bandages, eyewash fluids, and nitrile gloves. The median amount of DEHP leached into the simulant from the first aid samples was 0.35 μg (range: 0.02–2.80 μg), which was followed by DBP (0.12 μg), DiBP (0.07 μg), and DEP (0.05 μg). The amount of DEHP leached from first aid supplies was considerably lower than that from medical devices (Table 1).

The patterns of exposure to phthalates varied among medical product categories. The overall phthalate exposures via medical supplies were dominated by DEHP, with an average contribution of 98%. This profile is consistent with those published earlier for various medical devices such as transfusion sets, plastic supplies for IV infusion, hemodialysis sets, dialysis bags, and tubings, even though different leaching and extraction methods were applied in those studies. Generally, leached DEHP predominated in medical samples made of PVC or LDPE. The proportion of DEHP, DEP, DiBP, and DBP found in IV fluids was 88, 5.6, 3.6, and 2.5%, respectively. DEP, DiBP, and DBP were also found in plastic package made of PET. Phthalate exposures via first aid products were mainly contributed by DEHP (60%), DBP (20%), and DiBP (12%). Considering the variety of materials used in first aid products, phthalates other than DEHP are expected to be present. Phthalate exposure from creams/liquids was dominated by DEP with an average contribution of 99.5% (Figure 1a); this profile is similar to that reported for PCPs. Our results confirm the pattern of phthalate application in medical cream/liquid products.

The European Food Safety Authority (EFSA) has recommended tolerable daily intake (TDI) for DBP, BzBP, and DEHP at 10, 500, and 50 μg/kg bw/day, respectively. The U.S. Food and Drug Administration (FDA) suggested a TDI of 0.6 mg/kg bw/day for DEHP, with tolerable exposures of 42 mg/day for adults, 6 mg/day for children, and 2.1 mg/day for neonates (body masses of 70 kg for adults, 10 kg for children, and 3.5 kg for neonates).

Patients undergoing intensive therapeutic interventions can be exposed to higher levels of DEHP than the general population. A study reported that the maximum amount of DEHP exposure from blood bags was 0.7 mg/kg bw per use. In our study, the calculated median DEHP exposure dose for adults, toddlers, infants, and neonates from IV fluid infusions was 2.06, 11.3, 19.8, and 30.8 ng/kg bw per use event, respectively. The highest exposures were found for infants and neonates. Lower exposure doses calculated in our study can be attributed to the small median amount of phthalates leached into IV fluids in comparison to the earlier study that calculated based on blood stored in plastic bags for a long time. Thus, the duration of contact of fluids with plastic products and physicochemical properties of fluid can affect the amount leached into solution.

Chemicals can enter through cuts, punctures, or scrapes into the blood stream. First aid supplies such as bandage can be a direct source of exposure to phthalates. The calculated exposure doses to DEHP (5–40 ng/kg/day for adults and 40–280 ng/kg/day for children) and DBP (2–190 ng/kg/day for adults and 10–1340 ng/kg/day for children) via the use of first aid products were below the TDI for both adults and children (body weight of 70 kg for adults and 10 kg for children were used). No earlier studies have reported phthalate exposure from first aid kits, and this study shows that such exposures are not negligible.

On the basis of the median and maximum concentrations of phthalates measured in creams/liquids, we estimated the daily exposure dose of these chemicals through dermal absorption for adults, toddlers, infants, and neonates. The highest dermal DEP exposure dose via medical creams/liquids for adults, toddlers, infants, and neonates was 30, 300, 520, and 810 ng/kg bw/day, respectively. The highest dermal DEHP exposure dose via medical creams/liquids was 0.06, 0.6, 1, and 2 ng/kg bw/day, for adults, toddlers, infants, and neonates, respectively. Exposure doses calculated from these products for newborns were considerably higher than those for adults. Messerlian et al. reported that aqueous gel used for obstetrical ultrasound in pregnancy can be a source of maternal and fetal exposure to phthalates. In utero exposure can occur, as phthalates cross the placental barrier and have been detected in the cord blood and amniotic fluid.

Exposure doses to phthalates from the use of medical devices (including DEHP-free products) were calculated for adults, toddlers, infants, and neonates. Each device was assumed to be used once a day. The median exposure doses to DEHP from each medical device ranged from 0.001 to 0.96 μg/kg bw/day (Table 2), which were below the TDI value (0.6 mg/kg/day). Nevertheless, under maximum exposure scenarios (0.38–731 μg/kg bw/day), the doses exceeded the TDI value in certain cases, which suggests that the use of products containing high DEHP concentrations can pose health risks. The median EDIs of DEHP via nipples, baby pacifiers, and milk bottles were 0.14, 0.25, and 0.38 μg/kg bw/day, for toddlers, infants, and neonates, respectively. Among devices that contribute to direct exposure (e.g., catheters, cannulas, and tubings), the highest exposure to DEHP was from PVC-containing cannula, with the exposure dose calculated at 48.8, 267, 470, and 730 μg/kg bw/day for adults, toddlers, infants, and neonates, respectively. The DEHP exposure doses for neonates exceeded the TDI from the use of cannula. The total dermal DEHP exposure doses (sum of exposure from baby clothes/diapers, blood pressure cuffs/sensors, clinical care products [fluidized positioners/diapers/gloves] and creams/liquids) estimated for adults, toddlers, infants, and neonates were 0.01, 0.11, 0.20, and 0.31 μg/kg bw/day and 0.28, 2.93, 5.15, and 7.99 μg/kg bw/day, based on median and maximum amounts leached into the simulant, respectively. The sum of direct exposure doses from five categories of devices (nipples/pacifiers/milk bottles, tubings, catheters, connectors/extensions, and cannulas) analyzed in this study (Table 2, median: 0.11, 0.72, 1.26, and 1.96 μg/kg bw/day and maximum: 74.9, 415, 731, and 1130 μg/kg bw/day, for adults, toddlers, infants, and neonates, respectively) were lower than those previously reported for various medical products (5–8500 μg/kg bw/day for adults and 30–22,600 μg/kg bw/day for neonates) (Table S3). The differences can be attributed to the duration of contact, type/composition of the simulant, as well as the type of medical product tested. Furthermore, our exposure model for dermal contact did not account for the usage duration. Assuming that the highest amount of DEHP was released into the air stream through respiratory supplies, DEHP exposure doses via the respiratory support, namely, nebulizers, therapy filters, transfer sets, and expiratory filters, were estimated at 0.02, 1.39, 11.7 and 54.6 mg/day, respectively, which were similar in the range of those reported by Roth et al. (0.017 to 100 mg/day). Hill reported EDI of DEHP (0.0004 to 0.001 mg/kg/day for adults) for patients undergoing respiratory therapy, based on measured concentrations in air stream. The median and maximum daily exposures were estimated to be 0.08, 0.45, 0.79, and 1.23 and 0.68, 3.74, 6.58, and 10.2 μg/kg bw/day for adults, toddlers, infants, and newborns, respectively. The contribution of various sources [food, medical devices, nipples/baby pacifiers/milk bottles, and PCPs (including both rinse-off and leave-on)] to the total intake of DEHP is shown in Figure 1b–e (only direct exposure pathways were considered for medical devices). The contribution of medical devices to total DEHP exposure increased in the following order: adults < toddlers < infants < neonates. The results suggest elevated DEHP exposure among neonates via medical supplies. The principal route of exposure to DEHP for adults is diet, with an estimated daily dose of 0.25 mg. PCPs were the major sources of DEP and DBP exposure for adults, whereas nipples/baby pacifiers/milk bottles were the major sources of DBP and DiBP exposure for infants and neonates. The measured concentrations of DEHP in medical devices and IV fluids were lower than those reported in earlier studies (Table S3). The highest exposure doses to DEHP were reported from blood transfusions (using preserved blood in PVC blood bags) or hemodialysis. Different types of plastic materials have been reported to leach phthalates differently. For example, indwelling tubings can leach 21% of total DEHP content in 24 h of use, especially in lipophilic solutions such as parenteral solution or blood. The differences in concentrations measured in our study with those reported earlier may be related to the fact that we used more realistic migration and exposure scenarios, and tested different types of devices. Experimental conditions such as the type of simulants, surface area of products, and duration of contact can significantly influence the amount of phthalates leached. Furthermore, recent regulations on the use of phthalates in medical devices can be a factor in lower amounts found in our study. The high detection rates of DEHP in DEHP-free medical supplies may be a result of the sensitive analytical method used in our study. The median human exposure dose estimated via medical devices in this study was ∼157-fold higher for DEHP-containing products than DEHP-free products. However, this comparison was not based on the same type of medical devices. A median exposure dose of 0.53 μg/day via medical devices labeled DEHP-free is still of concern. Development of guidelines for an appropriate simulant and analytical method required for such assessments is needed. Although DBP, DEHP, and BBP were restricted in children’s toys at concentrations below 0.1%, regulations for phthalates in medical devices are needed. This is the first study to report exposure doses of phthalates via the use of various medical devices and supplies. However, the results should be interpreted with caution. We used an organic solvent-based simulant that may overestimate the amount of phthalates leached. Second, sample size was small for each type of medical device/product tested. Extrapolations were made for exposure calculations based on the migration levels in solutions. However, it should be noted that the occurrence of DEHP in medical devices (including those labeled DEHP-free) suggests the need for stringent regulations as these products constitute important sources of exposure in vulnerable populations, especially newborns. In summary, we document migration profiles of phthalates from various medical supplies. DEHP was found to be leached from 99% of medical supplies tested, even in those that were labeled “DEHP-free”. Exposure doses to DEHP from IV infusion fluids, medical creams/liquids, and first aid supplies were <0.3 μg/kg bw/day, whereas those from medical devices were in the range of 0.005–730 μg/kg bw/day, with the highest exposure doses from cannulas for newborns. The highest amount of DEHP leached from the respiratory support ranged from 0.02 to 54.6 mg/day from a single use. The sum of direct exposure to DEHP from various medical products tested ranged from 74.9 to 1130 μg/kg bw/day for different age groups, while the sum of dermal exposure ranged from 0.28 to 7.99 μg/kg bw/day. Exposure doses of newborns to DEHP from medical devices exceeded the tolerance levels set by the FDA, under the maximum exposure scenarios. It should be noted that our exposure calculations from the devices assumed incidental and single-use scenarios, but frequent and long-term exposures can occur among patients. While the European Commission has set specific migration limits for plastic materials and articles in contact with food, no such limits have been set for medical devices. Efforts should be made to regulate phthalates in medical devices, and the safety of other alternative plasticizers that are currently used as replacements should be examined. The chemical safety of medical devices is of vital importance to help safeguard the health of patients, especially newborns, and efforts are needed to address the critical issue urgently.